Vimpat Injection
Product Images NDC 0131-1810

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Vimpat (NDC 0131-1810). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Vimpat 01)

Chemical structure of lacosamide, the active ingredient in Vimpat tablets. The diagram shows molecular bonds and functional groups typical of lacosamide's chemical composition.*

FDA Label Image

Figure 1 (Vimpat 02)

A bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' compares placebo and Vimpat (lacosamide) at different doses across three studies. The vertical axis shows seizure reduction percentage, with Vimpat doses consistently showing higher median percent seizure reductions than placebo in each study group.*

FDA Label Image

Figure 2 (Vimpat 03)

A line graph showing the proportion of patients by responder rate (equal to or greater improvement) comparing Vimpat (lacosamide) at daily doses of 200 mg, 400 mg, and 600 mg versus placebo. The x-axis represents percent of patients from 100% to 0%, and the y-axis shows responder rate from worsening (-100%) to improvement (100%). Four lines indicate responder rates for placebo and three Vimpat dose groups from studies 2, 3, and 4.*

FDA Label Image

Figure 3 (Vimpat 04)

A Kaplan-Meier survival curve comparing the proportion of patients over time (days) between Vimpat and placebo groups. The graph includes risk numbers at various time points and statistical values including a p-value, hazard ratio with risk reduction percentage, and confidence interval, illustrating patient outcomes during the study period.*

FDA Label Image

Principal Display Panel (50 mg Tablet Blister Card Carton)

Label for Vimpat (lacosamide) tablets, 50 mg strength, film-coated oral tablets. The label includes an image of a pink oval tablet marked with '50'. The package contains 60 tablets. Labeler is UCB, Inc. The label also advises to see the package insert for dosage information and includes storage instructions and a barcode.*

FDA Label Image

Principal Display Panel (100 mg Tablet Blister Card Carton)

Vimpat 100 mg film-coated tablets label showing one yellow oval tablet embossed with "100." The label includes the active ingredient lacosamide, specifies oral route, and states "Rx only." Packaging is for 60 tablets, manufactured for UCB, Inc., Smyrna, GA, with dosage instructions directing users to the package insert.*

FDA Label Image

Pprincipal Display Panel (150 mg Tablet Blister Card Carton)

Vimpat 150 mg film-coated tablets packaging label shows the product name, active ingredient lacosamide, strength 150 mg, and oral dosage form. The label includes an image of a tan oblong tablet marked "150," notes the package contains 60 tablets, and states the drug is Rx only. It is manufactured by UCB, Inc., Smyrna, GA. Storage and pharmacist attention warnings are also visible.*

FDA Label Image

Principal Display Panel (200 mg Tablet Blister Card Carton)

Label for Vimpat (lacosamide) tablets, 200 mg film-coated oral tablets. The label indicates a package size of 60 tablets and includes the National Drug Code (NDC) 0131-2480-35. It notes that each tablet contains 200 mg lacosamide and directs users to the package insert for dosage information. The product is labeled Rx only and manufactured for UCB, Inc., Smyrna, GA.*

FDA Label Image

Principal Display Panel (20 mL Vial Carton)

Box packaging label for VIMPAT (lacosamide) injection, 200 mg per 20 mL (10 mg/mL) solution for intravenous use. The label indicates 10 single-dose vials and is manufactured for UCB, Inc. The design includes dosage information, storage instructions, and inactive ingredients.*

FDA Label Image

Principal Display Panel (200 mL Bottle Label)

Label for Vimpat (lacosamide) oral solution, 10 mg/mL, manufactured for UCB, Inc. The label includes dosage strength, volume (465 mL), storage instructions, and important dispensing information. It also contains warnings about phenylketonurics and product discard timing. The label displays the NDC 0131-5410-70 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.